vTv Therapeutics Inc.

NasdaqCM:VTVT Stock Report

Market Cap: US$46.5m

vTv Therapeutics Management

Management criteria checks 2/4

vTv Therapeutics' CEO is Paul Sekhri, appointed in Aug 2022, has a tenure of 2.25 years. total yearly compensation is $650.91K, comprised of 73.7% salary and 26.3% bonuses, including company stock and options. directly owns 0.6% of the company’s shares, worth $280.93K. The average tenure of the management team and the board of directors is 1.9 years and 0.8 years respectively.

Key information

Paul Sekhri

Chief executive officer

US$650.9k

Total compensation

CEO salary percentage73.7%
CEO tenure2.3yrs
CEO ownership0.6%
Management average tenure1.9yrs
Board average tenureless than a year

Recent management updates

Recent updates

Here's Why We're Watching vTv Therapeutics' (NASDAQ:VTVT) Cash Burn Situation

Aug 24
Here's Why We're Watching vTv Therapeutics' (NASDAQ:VTVT) Cash Burn Situation

Will vTv Therapeutics (NASDAQ:VTVT) Spend Its Cash Wisely?

May 11
Will vTv Therapeutics (NASDAQ:VTVT) Spend Its Cash Wisely?

vTv Therapeutics GAAP EPS of -$0.04

Aug 16

vTv stock soars 18% on $10M equity investment by CinRx Pharma

Jul 25

We Think vTv Therapeutics (NASDAQ:VTVT) Needs To Drive Business Growth Carefully

Aug 17
We Think vTv Therapeutics (NASDAQ:VTVT) Needs To Drive Business Growth Carefully

The Director of vTv Therapeutics Inc. (NASDAQ:VTVT), Richard Nelson, Just Bought A Few More Shares

Mar 03
The Director of vTv Therapeutics Inc. (NASDAQ:VTVT), Richard Nelson, Just Bought A Few More Shares

vTv Therapeutics inks licensing deal for HPP971, shares up 11%

Dec 15

MacAndrews & Forbes buys 625K shares of vTv Therapeutics

Dec 11

CEO Compensation Analysis

How has Paul Sekhri's remuneration changed compared to vTv Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$18m

Jun 30 2024n/an/a

-US$20m

Mar 31 2024n/an/a

-US$21m

Dec 31 2023US$651kUS$480k

-US$20m

Sep 30 2023n/an/a

-US$22m

Jun 30 2023n/an/a

-US$19m

Mar 31 2023n/an/a

-US$17m

Dec 31 2022US$2mUS$200k

-US$19m

Compensation vs Market: Paul's total compensation ($USD650.91K) is about average for companies of similar size in the US market ($USD653.78K).

Compensation vs Earnings: Paul's compensation has been consistent with company performance over the past year.

CEO

Paul Sekhri (66 yo)

2.3yrs

Tenure

US$650,913

Compensation

Mr. Paul J. Sekhri, M.Sc. is Director of Quercis Pharma AG. Mr. Sekhri is Director at AdhereTech Inc. since February 7, 2024. He serves as Chief Executive Officer, President & Director of vTv Therapeutics...

Leadership Team

NamePositionTenureCompensationOwnership
Paul Sekhri
CEO, President & Chairman of the Board2.3yrsUS$650.91k0.60%
$ 280.9k
Steven Tuch
Executive VP & CFO1.9yrsUS$465.25k0.21%
$ 99.6k
Carmen Valcarce
Chief Scientific Officer & Executive VPno datano datano data
Elizabeth Keiley
Executive VP & General Counsel1.8yrsno datano data
Richard Nelson
Executive VP of Corporate Development & Director2.3yrsUS$547.40k0.45%
$ 208.0k
Thomas Strack
Chief Medical Officerless than a yearno datano data

1.9yrs

Average Tenure

56.5yo

Average Age

Experienced Management: VTVT's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Paul Sekhri
CEO, President & Chairman of the Board2.3yrsUS$650.91k0.60%
$ 280.9k
Richard Nelson
Executive VP of Corporate Development & Director4yrsUS$547.40k0.45%
$ 208.0k
Daniel Spiegelman
Directorless than a yearno datano data
Srinivas Akkaraju
Independent Directorless than a yearno datano data
Anne Phillips
Independent Directorless than a yearno datano data
Raymond Cheong
Lead Independent Directorless than a yearno datano data
Fahed Al-Marzooqi
Independent Director2.3yrsUS$87.63k0.026%
$ 12.0k

0.8yrs

Average Tenure

56yo

Average Age

Experienced Board: VTVT's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.